2 Followers on Owler
ARS is a clinical-stage pharmaceutical firm that develops intranasal epinephrine spray for the treatment of allergic reactions...
Read moreARS is a clinical-stage pharmaceutical firm that develops intranasal epinephrine spray for the treatment of allergic reactions...
Read more
President & CEO
Richard Lowenthal
News
May 28, 2023
GlobalNewswire
Press Release: ARS Pharmaceuticals : SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY
May 15, 2023
Zacks
ARS Pharmaceuticals: ARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Spray
May 15, 2023
centralcharts
Press Release: ARS Pharmaceuticals : ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
May 14, 2023
Medthority
ARS Pharmaceuticals: FDA Advisory Committee votes in support of favorable bnefit-risk profile for neffy (intranasal for the treatment of allergic reactions (type 1), including anaphylaxis.-
ARS Pharmaceuticals, Inc
May 12, 2023
MarketScreener
ARS Pharmaceuticals: INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
May 12, 2023
MarketScreener
ARS Pharmaceuticals: ARS Pharmaceuticals Soar 68% in Premarket Trading as FDA Panel Backs Neffy
May 11, 2023
NewsFile
Press Release: ARS Pharmaceuticals : ARS Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
May 09, 2023
Benzinga
ARS Pharmaceuticals: FDA Issues Some Concerns Regarding ARS Pharma's Investigational Allergy Treatment
Apr 28, 2023
Americanbankingnews
ARS Pharmaceuticals: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) to Post Q1 2023 Earnings of ($0.13) Per Share, SVB Leerink Forecasts
Mar 28, 2023
MarketScreener
ARS Pharmaceuticals: ARS Pharmaceuticals Gets FDA Committee Meeting for Neffy
ARS Pharmaceuticals Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to ARS Pharmaceuticals?
ARS Pharmaceuticals Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$ < 1M
ARS Pharmaceuticals's revenue is the ranked 15th among it's top 10 competitors. The top 10 competitors average 80.4M. Over the last two quarters, ARS Pharmaceuticals's revenue has decreased by 98.5%. Specifically, in Q1 2023's revenue was $ < 1M; in Q4 2022, it was $1.3M.
ARS Pharmaceuticals News
ARS Pharmaceuticals Press Releases
ARS Pharmaceuticals Headquarters
ARS Pharmaceuticals Summary
ABOUT
Overview
ARS is a clinical-stage pharmaceutical firm that develops intranasal epinephrine spray for the treatment of allergic reactions. ARS Pharmaceuticals was founded in 2015. ARS Pharmaceuticals' headquarters is located in San Diego, California, USA 92130. ...CEO
ARS Pharmaceuticals's President & CEO, Richard Lowenthal, currently has an approval rating of 70%. ARS Pharmaceuticals's primary competitors are Similasan Corporation, KC Pharmaceuticals, Trusted Tablets and 17 more.Website
ars-pharma.comAcquisitions
There have been no acquisitions found related to ARS PharmaceuticalsInvestments
Recent investment data cannot be found related to ARS PharmaceuticalsFrequently Asked Questions about ARS Pharmaceuticals
When was ARS Pharmaceuticals founded?
ARS Pharmaceuticals was founded in 2015Who is ARS Pharmaceuticals's CEO?
ARS Pharmaceuticals's CEO is Richard LowenthalHow much revenue does ARS Pharmaceuticals generate?
ARS Pharmaceuticals generates $ < 1M in revenueHow much funding does ARS Pharmaceuticals have?
ARS Pharmaceuticals has historically raised $83.2M in funding
Where is ARS Pharmaceuticals's headquarters?
ARS Pharmaceuticals's headquarters is in San Diego California, USAHow many employees does ARS Pharmaceuticals have?
ARS Pharmaceuticals has 90 employeesWhat sector does ARS Pharmaceuticals operate in?
ARS Pharmaceuticals is in PharmaceuticalsWho are ARS Pharmaceuticals's competitors?
ARS Pharmaceuticals's top competitors are Similasan Corporation, KC Pharmaceuticals, Trusted Tablets